News und Analysen
Evotec: Vorstand streckt Fühler nach Antisense-Startup aus
Evotec (WKN: 566480) geht seine nächste strategische Partnerschaft ein. So wurde, wie heute vermeldet, mit dem Marburger Next-Generation-Wirkstoffforscher Secarna Pharmaceuticals eine Kooperation im
QIAGEN Reports Full Results for Second Quarter and First Half Of 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced full results of operations for the second quarter and first half of 2020, with net sales and adjusted earnings per share (EPS) in
Xencor Reports Second Quarter 2020 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial
QIAGEN meldet vollständige Ergebnisse des zweiten Quartals und des ersten Halbjahrs 2020
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die vollständigen Ergebnisse der operativen Tätigkeit für das zweite Quartal und das erste Halbjahr 2020 bekannt, wobei der
Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that it has raised $22.2 million (€ 19
Antibe Therapeutics Provides Corporate Update
Antibe Therapeutics Inc.:
- Phase II secondary data confirmed remarkable potency of ATB-346 -
- 3rd party commercial studies project peak annual sales of $5.3 billion across seven key countries
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at
Bayer: Diese Gewinnwarnung ist gar nicht das Problem!
Der Leverkusener Chemie- und Pharmagigant Bayer (WKN: BAY001) legte heute früh seine aktuellen Quartalszahlen vor. Demnach wurde in Q2 ein Umsatz in Höhe von 10,05 Milliarden Euro bei einem EBIT von
CO.DON AG: Erfolgreiche Hauptversammlung 2020
Berlin / Teltow / Leipzig, 04. August 2020 - Am 30. Juli 2020 fand in Berlin unter der Leitung des stellvertretenden Aufsichtsratsvorsitzenden Herrn Stählin die diesjährige Hauptversammlung
Neutrisci Receives Final Approval from The Japanese Health Ministry
Vancouver, British Columbia – August 4, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company
NeutriSci erhält vom japanischen Gesundheitsministerium die finale Produktzulassung
Vancouver, British Columbia – 4. August 2020 – NeutriSci International Inc. („NeutriSci“ oder das „Unternehmen“) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), ein innovatives
IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious
Trevena vor FDA-Entscheidung: +331% nach NBC-Empfehlung!
Woche der Wahrheit für Trevena (WKN: A1XDSL): Die US-Gesundheitsbehörde wird bis Freitag über die Zulassung des Schmerzmittels Oliceridine entscheiden.
Bis 2,89 USD geht es für die Trevena-Aktie
Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced that the U.S. Food
Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based
Savara to Report Second Quarter 2020 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize
Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets
Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2020, highlighting revenue growth and financial strength as well as the advancement of the company’s clinical
THERANEXUS TO PRESENT THE RESULTS OF THN102 FOR PARKINSON'S DISEASE AT THE 2020 INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS
The MDS Virtual Congress will take place from 12 to 16 September 2020.
Lyon, 30 July 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer
Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market
IMV to Present at BTIG’s Virtual Biotechnology Conference
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will present at BTIG’s Virtual
Sensorion appoints five renowned experts to its Scientific Advisory Board
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will
VALBIOTIS meldet einen Kassenstand von 10,9 Millionen Euro zum 30. Juni 2020
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von